News & Videos - VERITAS PHARMA INC VRTHF - Page 4

VANCOUVER, BC / ACCESSWIRE / November 21, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), ("Veritas" or the "Company"), an emerging-stage pharmaceutical and IP development company, is pleased to announce that it has signed a Letter of Intent ("LOI") with Sechelt Organic Marijuana Inc. ("Privco"), whereby Veritas has been granted the exclusive option to acquire 100% ownership of PrivCo (the "Transaction"), subject to certain terms and conditions including; obtaining an...

VANCOUVER, BC / ACCESSWIRE / November 16, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), an emerging discovery and IP development company, has expanded the private placement offering announced on September 16 th and has engaged the European Healthcare Capital ("EHC") to grow investor awareness of medical marijuana industry. The expansion to the private placement will be for an additional one-month period from the date of this announcement and will expand to 4,750,000 units...

VANCOUVER, BC / ACCESSWIRE / November 9, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP), ("Veritas" or the "Company"), as a result of a review by the British Columbia Securities Commission, is issuing the following press release to clarify our disclosure. We have amended and restated our Management Discussion and Analysis ("MD&A") to more fully disclose the effect of the advances by the Company to CTL. The MD&A has also been updated to increase the disclosure on the related...

Cannevert Delivers Its Quarterly Research Report PR Newswire VANCOUVER, Oct. 5, 2016 A Number of Cannabis Strains Identified as Potentially Therapeutic VANCOUVER , Oct. 5, 2016 /PRNewswire/ - Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt : 2VP), ("Veritas" or the "Company") announces that it has received a quarterly research report from Cannevert Therapeutics Limited (CTL), lead researcher for Veritas. The report outlines both general and scientific progress since their last update....

DGAP-News: Veritas Pharma Inc. / Key word(s): Miscellaneous Veritas Approves Issue of Stock Options 06.09.2016 / 15:01 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - September 6, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FSE: 2VP) ('VRT' or the 'Company'), an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis...

VANCOUVER, BC / ACCESSWIRE / September 6, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FSE: 2VP) ("VRT" or the "Company"), an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy, today announced that 1,000,000 stock options have been issued; 200,000 each to its two new directors; Dr. Don Carlow and Mr. Matthew Hamilton; as well as 300,000 to the Company's Chief...

DGAP-News: Veritas Pharma Inc. / Key word(s): Miscellaneous Veritas Pharma Inc. Exclusive Partner Qualifies For Non-Dilutive Grant 23.08.2016 / 14:01 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - August 23, 2016) - Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP) ('Veritas' or the 'Company'), an emerging discovery and IP development company, has announced that Cannevert Therapeutics Ltd., the Company's exclusive...

VANCOUVER, BC / ACCESSWIRE / August 23, 2016 / Veritas Pharma Inc. (CSE: VRT) (OTC Pink: VRTHF) (FSE: 2VP) ("Veritas" or the "Company"), an emerging discovery and IP development company, has announced that Cannevert Therapeutics Ltd., the Company's exclusive partner and high-level R&D arm, has been awarded a research grant through Mitacs Inc. for research and development work related to the discovery of new cannabis strains for specific disease conditions. Mitacs is a national not-for-profit...

Veritas Pharma Embarks on Important Next Phase of Cannabis Research PR Newswire VANCOUVER, August 3, 2016 VANCOUVER , August 3, 2016 /PRNewswire/ -- Veritas Pharma Inc. ("VRT" or the "Company") (CSE: VRT; OTC: VRTHF; and Frankfurt : 2VP) is pleased to announce that through Cannevert Therapeutics Ltd, Veritas' research arm, has developed several candidate cannabis strains and is now fully engaged in chemical and biological assessment of these key strains. While chemical assays allow for...